Reflections on market access for personalized medicine: Recommendations for Europe

Katherine Payne, Lieven Annemans

    Research output: Contribution to journalArticlepeer-review

    Abstract

    This article aims to provide an overview of the current literature focusing on the reimbursement of personalized medicine across the European Union. The article starts by describing types of perspectives that are possible (general public, patient, payer, provider, service commissioner, and policymaker). The description of perspectives also explains the importance of understanding the different possible decision criteria and processes from the various perspectives by taking into account budget constraints. The article then focuses on an example of personalized medicine, namely, the use of companion diagnostic-medicine combinations, to describe the role of reimbursement/payer agencies across the European Union to control the introduction and coverage of such companion diagnostic-medicine technologies. The article touches on the strategic challenges and the use of economic evidence to introduce personalized medicine from a health policy perspective. The article also draws on empirical studies that have explored patients' and clinicians' views of examples of personalized medicine to illustrate the challenges for developing patient-centered and timely health care services. © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
    Original languageEnglish
    Pages (from-to)S32-S38
    JournalValue in Health
    Volume16
    Issue number6
    DOIs
    Publication statusPublished - Sep 2013

    Keywords

    • economic evaluation
    • personalized medicine
    • reimbursement

    Fingerprint

    Dive into the research topics of 'Reflections on market access for personalized medicine: Recommendations for Europe'. Together they form a unique fingerprint.

    Cite this